Skip to main content
SpringerLink
Log in

Changing Trends in the Epidemiology of Endometrial Cancer

  • Chapter
  • First Online:
Recent Advances in Endometrial Cancer

  • 435 Accesses

Abstract

Uterine corpus cancer (UCC) is the 6th most common female malignancy worldwide and the 14th most deadly. Importantly, UCC represents a significant locus of health disparities both globally and within the United States, with notable differences seen in both its geographical incidence and in outcomes between various racial/ethnic cohorts. UCC is categorized into Type I and Type II carcinomas, each with its own idiosyncratic presentation, epidemiologic risk factors, and prognosis. Type II carcinomas are rarer, and typically arise in older patients in the setting of an atrophic endometrium. Type I carcinomas are more common and are thought to arise due to chronic exposure to estrogen unopposed by a progestogen, with various potential risk factors tied to either endogenous or exogenous estrogen exposure. This chapter presents the most recent epidemiologic data regarding UCC, briefly introduces the many avenues of investigation that have been conducted into its risk factors, and summarizes the most recent findings on each topic. Particular attention is devoted to the role that geographic and racial/ethnic differences play in UCC risk factors and outcomes, and because UCC incidence is higher in Western and more industrialized countries, this chapter examines obesity, diabetes mellitus, and various lifestyle factors that are especially relevant to these regions. Also considered is the impact of estrogen-modifying therapies (e.g., oral contraceptives, hormone replacement therapy, tamoxifen, and aromatase inhibitors) on UCC risk. Finally, the most up-to-date information on the role of parity, contraception, and sterilization is presented, with careful attention paid to genetic syndromes as well.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26(4):444–57.

    PubMed  Google Scholar 

  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    PubMed  Google Scholar 

  3. Henley SJ, Miller JW, Dowling NF, Benard VB, Richardson LC. Uterine cancer incidence and mortality – United States, 1999-2016. MMWR Morb Mortal Wkly Rep. 2018;67(48):1333–8.

    PubMed  PubMed Central  Google Scholar 

  4. American Cancer Society. Cancer Facts & Figures 2018. Atlanta: American Cancer Society; 2018.

    Google Scholar 

  5. Cancer Stat Facts: Uterine cancer. SEER [Internet]. 2019. https://seer.cancer.gov/statfacts/html/corp.html. Accessed 10 Apr 2019

  6. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol. 1982;6(2):93–108.

    CAS  PubMed  Google Scholar 

  7. Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med. 1981;105(11):615–8.

    CAS  PubMed  Google Scholar 

  8. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.

    CAS  PubMed  Google Scholar 

  9. Boruta DM II, Gehrig PA, Fader AN, Olawaiye AB. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009;115(1):142–53.

    PubMed  Google Scholar 

  10. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851–6.

    PubMed  PubMed Central  Google Scholar 

  11. McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev. 2008;17(1):73–9.

    CAS  PubMed  Google Scholar 

  12. Ko EM, Walter P, Clark L, Jackson A, Franasiak J, Bolac C, et al. The complex triad of obesity, diabetes and race in Type I and II endometrial cancers: prevalence and prognostic significance. Gynecol Oncol. 2014;133(1):28–32.

    PubMed  Google Scholar 

  13. Lachance JA, Everett EN, Greer B, Mandel L, Swisher E, Tamimi H, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2006;101(3):470–5.

    CAS  PubMed  Google Scholar 

  14. Bjorge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer. 2007;120(2):378–83.

    PubMed  Google Scholar 

  15. Cao QJ, Belbin T, Socci N, Balan R, Prystowsky MB, Childs G, et al. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol. 2004;23(4):321–9.

    PubMed  Google Scholar 

  16. O’Hara AJ, Bell DW. The genomics and genetics of endometrial cancer. Adv Genomics Genet. 2012;2012(2):33–47.

    PubMed  PubMed Central  Google Scholar 

  17. Odicino FE, Bignotti E, Rossi E, Pasinetti B, Tassi RA, Donzelli C, et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer. 2008;18(1):14–21.

    CAS  PubMed  Google Scholar 

  18. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104(7):1391–7.

    CAS  PubMed  Google Scholar 

  19. Singh P, Smith CL, Cheetham G, Dodd TJ, Davy ML. Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. Int J Gynecol Cancer. 2008;18(6):1344–51.

    CAS  PubMed  Google Scholar 

  20. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22(15):3126–32.

    CAS  PubMed  Google Scholar 

  21. Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer. 2006;16(5):1897–902.

    CAS  PubMed  Google Scholar 

  22. Maxwell GL, Tian C, Risinger J, Brown CL, Rose GS, Thigpen JT, et al. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer. 2006;107(9):2197–205.

    PubMed  Google Scholar 

  23. Abeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 1991;40(3):207–17.

    CAS  PubMed  Google Scholar 

  24. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S105–43.

    PubMed  Google Scholar 

  25. Slomovitz BM, Burke TW, Eifel PJ, Ramondetta LM, Silva EG, Jhingran A, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91(3):463–9.

    PubMed  Google Scholar 

  26. Thomas M, Mariani A, Wright JD, Madarek EO, Powell MA, Mutch DG, et al. Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol. 2008;108(2):293–7.

    CAS  PubMed  Google Scholar 

  27. Creasman WT, Kohler MF, Odicino F, Maisonneuve P, Boyle P. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004;95(3):593–6.

    PubMed  Google Scholar 

  28. Dunton CJ, Balsara G, McFarland M, Hernandez E. Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv. 1991;46(2):97–102.

    CAS  PubMed  Google Scholar 

  29. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Gehrig PA, Bae-Jump VL, Boggess JF, Groben PA, Fowler WC Jr, Van Le L. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol. 2004;94(1):208–11.

    PubMed  Google Scholar 

  31. Levine DA, Lin O, Barakat RR, Robson ME, McDermott D, Cohen L, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol. 2001;80(3):395–8.

    CAS  PubMed  Google Scholar 

  32. Chan JK, Manuel MR, Cheung MK, Osann K, Husain A, Teng NN, et al. Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol Oncol. 2006;102(3):508–12.

    PubMed  Google Scholar 

  33. Goshen R, Chu W, Elit L, Pal T, Hakimi J, Ackerman I, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol. 2000;79(3):477–81.

    CAS  PubMed  Google Scholar 

  34. Gallup DG, Stock RJ. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol. 1984;64(3):417–20.

    CAS  PubMed  Google Scholar 

  35. Schmeler KM, Soliman PT, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Endometrial cancer in young, normal-weight women. Gynecol Oncol. 2005;99(2):388–92.

    PubMed  Google Scholar 

  36. Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105(3):575–80.

    PubMed  Google Scholar 

  37. La Vecchia C, Franceschi S, Gallus G, Decarli A, Colombo E, Liberati A, et al. Prognostic features of endometrial cancer in estrogen users and obese women. Am J Obstet Gynecol. 1982;144(4):387–90.

    PubMed  Google Scholar 

  38. Yap OW, Matthews RP. Racial and ethnic disparities in cancers of the uterine corpus. J Natl Med Assoc. 2006;98(12):1930–3.

    PubMed  PubMed Central  Google Scholar 

  39. Allard JE, Maxwell GL. Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control. 2009;16(1):53–6.

    PubMed  Google Scholar 

  40. Jamison PM, Noone AM, Ries LA, Lee NC, Edwards BK. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev. 2013;22(2):233–41.

    PubMed  Google Scholar 

  41. Keshavarz H, Hillis SD, Kieke BA, Marchbanks PA. Hysterectomy [Internet]. 2002. https://www.cdc.gov/mmwr/preview/mmwrhtml/ss5105a1.htm. Accessed 26 Feb 2016.

  42. Elshaikh MA, Munkarah AR, Robbins JR, Laser BS, Bhatt N, Cogan C, et al. The impact of race on outcomes of patients with early stage uterine endometrioid carcinoma. Gynecol Oncol. 2013;128(2):171–4.

    PubMed  Google Scholar 

  43. Smotkin D, Nevadunsky NS, Harris K, Einstein MH, Yu Y, Goldberg GL. Histopathologic differences account for racial disparity in uterine cancer survival. Gynecol Oncol. 2012;127(3):616–9.

    PubMed  Google Scholar 

  44. Baskovic M, Lichtensztajn DY, Nguyen T, Karam A, English DP. Racial disparities in outcomes for high-grade uterine cancer: a California cancer registry study. Cancer Med. 2018;7(9):4485–95.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Ferguson SE, Olshen AB, Levine DA, Viale A, Barakat RR, Boyd J. Molecular profiling of endometrial cancers from African-American and Caucasian women. Gynecol Oncol. 2006;101(2):209–13.

    CAS  PubMed  Google Scholar 

  46. Maxwell GL, Risinger JI, Hayes KA, Alvarez AA, Dodge RK, Barrett JC, et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin Cancer Res. 2000;6(8):2999–3005.

    CAS  PubMed  Google Scholar 

  47. Randall TC, Armstrong K. Differences in treatment and outcome between African-American and white women with endometrial cancer. J Clin Oncol. 2003;21(22):4200–6.

    PubMed  Google Scholar 

  48. Hicks ML, Phillips JL, Parham G, Andrews N, Jones WB, Shingleton HM, et al. The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer. 1998;83(12):2629–37.

    CAS  PubMed  Google Scholar 

  49. Fader AN, Habermann EB, Hanson KT, Lin JF, Grendys EC, Dowdy SC. Disparities in treatment and survival for women with endometrial cancer: a contemporary national cancer database registry analysis. Gynecol Oncol. 2016;143(1):98–104.

    PubMed  Google Scholar 

  50. Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G, et al. Cancer Statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 2018;68(6):425–45.

    PubMed  Google Scholar 

  51. Malagon-Blackwell EM, Seagle BL, Nieves-Neira W, Shahabi S. The Hispanic Paradox in endometrial cancer: a National Cancer Database study. Gynecol Oncol. 2017;146(2):351–8.

    PubMed  Google Scholar 

  52. Rodriguez AM, Schmeler KM, Kuo YF. Disparities in endometrial cancer outcomes between non-Hispanic White and Hispanic women. Gynecol Oncol. 2014;135(3):525–33.

    PubMed  Google Scholar 

  53. Bregar AJ, Alejandro Rauh-Hain J, Spencer R, Clemmer JT, Schorge JO, Rice LW, et al. Disparities in receipt of care for high-grade endometrial cancer: a National Cancer Data Base analysis. Gynecol Oncol. 2017;145(1):114–21.

    PubMed  Google Scholar 

  54. Schlumbrecht M, BaekerBispo JA, Balise RR, Huang M, Slomovitz B, Kobetz E. Variation in type II endometrial cancer risk by Hispanic subpopulation: an exploratory analysis. Gynecol Oncol. 2017;147(2):329–33.

    PubMed  Google Scholar 

  55. Pinheiro PS, Callahan KE, Siegel RL, Jin H, Morris CR, Trapido EJ, et al. Cancer mortality in hispanic ethnic groups. Cancer Epidemiol Biomarkers Prev. 2017;26(3):376–82.

    PubMed  PubMed Central  Google Scholar 

  56. Cook LS, Nelson HE, Cockburn M, Olson SH, Muller CY, Wiggins CL. Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites. Cancer Causes Control. 2013;24(1):61–9.

    PubMed  Google Scholar 

  57. Mahdi H, Hou H, Kowk LL, Moslemi-Kebria M, Michener C. Type II endometrial cancer in Hispanic women: tumor characteristics, treatment and survival compared to non-Hispanic white women. Gynecol Oncol. 2014;133(3):512–7.

    PubMed  Google Scholar 

  58. Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66(3):182–202.

    PubMed  PubMed Central  Google Scholar 

  59. Mahdi H, Schlick CJ, Kowk LL, Moslemi-Kebria M, Michener C. Endometrial cancer in Asian and American Indian/Alaskan Native women: tumor characteristics, treatment and outcome compared to non-Hispanic white women. Gynecol Oncol. 2014;132(2):443–9.

    PubMed  Google Scholar 

  60. Kost ER, Hall KL, Hines JF, Farley JH, Nycum LR, Rose GS, et al. Asian-Pacific Islander race independently predicts poor outcome in patients with endometrial cancer. Gynecol Oncol. 2003;89(2):218–26.

    PubMed  Google Scholar 

  61. Norris T, Vines P, Hoeffel E. The American Indian and Alaska Native Population: 2010. United States Census Bureau; 2012.

    Google Scholar 

  62. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res. 1982;42(8):3232–9.

    CAS  PubMed  Google Scholar 

  63. Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res. 1978;38(11 Pt 2):4360–6.

    CAS  PubMed  Google Scholar 

  64. Herrinton LJ, Weiss NS. Postmenopausal unopposed estrogens. Characteristics of use in relation to the risk of endometrial carcinoma. Ann Epidemiol. 1993;3(3):308–18.

    CAS  PubMed  Google Scholar 

  65. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med. 1980;302(10):551–4.

    CAS  PubMed  Google Scholar 

  66. Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57(2):205–12.

    CAS  PubMed  PubMed Central  Google Scholar 

  67. Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev. 2012;(8):Cd000402.

    Google Scholar 

  68. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst. 1997;89(15):1110–6.

    CAS  PubMed  Google Scholar 

  69. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer. 2004;108(3):425–32.

    CAS  PubMed  Google Scholar 

  70. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst. 1996;88(16):1127–35.

    CAS  PubMed  Google Scholar 

  71. Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–58.

    PubMed  PubMed Central  Google Scholar 

  72. Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: a population-based cohort study in Taiwan. Medicine (Baltimore). 2018;97(39):e12608.

    PubMed  PubMed Central  Google Scholar 

  73. Yin W, Falconer H, Yin L, Xu L, Ye W. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol. 2019;5(1):106–7.

    PubMed  Google Scholar 

  74. Fader AN, Arriba LN, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol. 2009;114(1):121–7.

    PubMed  Google Scholar 

  75. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.

    PubMed  Google Scholar 

  76. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer–viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–8.

    PubMed  PubMed Central  Google Scholar 

  77. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet. 2005;366(9484):491–505.

    PubMed  Google Scholar 

  78. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer. 2001;84(7):975–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Modugno F, Ness RB, Chen C, Weiss NS. Inflammation and endometrial cancer: a hypothesis. Cancer Epidemiol Biomarkers Prev. 2005;14(12):2840–7.

    CAS  PubMed  Google Scholar 

  80. Folsom AR, Kaye SA, Potter JD, Prineas RJ. Association of incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women’s Health Study. Cancer Res. 1989;49(23):6828–31.

    CAS  PubMed  Google Scholar 

  81. Gredmark T, Kvint S, Havel G, Mattsson LA. Adipose tissue distribution in postmenopausal women with adenomatous hyperplasia of the endometrium. Gynecol Oncol. 1999;72(2):138–42.

    CAS  PubMed  Google Scholar 

  82. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78.

    PubMed  Google Scholar 

  83. Schouten LJ, Goldbohm RA, van den Brandt PA. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands cohort study. Int J Gynecol Cancer. 2006;16(Suppl 2):492.

    PubMed  Google Scholar 

  84. Park SL, Goodman MT, Zhang ZF, Kolonel LN, Henderson BE, Setiawan VW. Body size, adult BMI gain and endometrial cancer risk: the multiethnic cohort. Int J Cancer. 2010;126(2):490–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Setiawan VW, Pike MC, Kolonel LN, Nomura AM, Goodman MT, Henderson BE. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol. 2007;165(3):262–70.

    PubMed  Google Scholar 

  86. Everett E, Tamimi H, Greer B, Swisher E, Paley P, Mandel L, et al. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2003;90(1):150–7.

    CAS  PubMed  Google Scholar 

  87. Sturgeon SR, Sherman ME, Kurman RJ, Berman ML, Mortel R, Twiggs LB, et al. Analysis of histopathological features of endometrioid uterine carcinomas and epidemiologic risk factors. Cancer Epidemiol Biomarkers Prev. 1998;7(3):231–5.

    CAS  PubMed  Google Scholar 

  88. Weiss JM, Saltzman BS, Doherty JA, Voigt LF, Chen C, Beresford SA, et al. Risk factors for the incidence of endometrial cancer according to the aggressiveness of disease. Am J Epidemiol. 2006;164(1):56–62.

    PubMed  Google Scholar 

  89. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311(8):806–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Sponholtz TR, Palmer JR, Rosenberg L, Hatch EE, Adams-Campbell LL, Wise LA. Body size, metabolic factors, and risk of endometrial cancer in black women. Am J Epidemiol. 2016;183(4):259–68.

    PubMed  PubMed Central  Google Scholar 

  91. Karageorgi S, Hankinson SE, Kraft P, De Vivo I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses’ Health Study cohort 1976-2004. Int J Cancer. 2010;126(1):208–16.

    CAS  PubMed  PubMed Central  Google Scholar 

  92. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women’s Health Study. Am J Epidemiol. 1996;143(12):1195–202.

    CAS  PubMed  Google Scholar 

  93. Zanagnolo V, Pasinetti B, Sartori E. Clinical review of 63 cases of sex cord stromal tumors. Eur J Gynaecol Oncol. 2004;25(4):431–8.

    CAS  PubMed  Google Scholar 

  94. Podfigurna-Stopa A, Czyzyk A, Katulski K, Moszynski R, Sajdak S, Genazzani AR, et al. Recurrent endometrial hyperplasia as a presentation of estrogen-secreting the coma – case report and mini review of the literature. Gynecol Endocrinol. 2016;32(3):184–7.

    PubMed  Google Scholar 

  95. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21(6):1180–9.

    PubMed  Google Scholar 

  96. Evans AT III, Gaffey TA, Malkasian GD Jr, Annegers JF. Clinicopathologic review of 118 granulosa and 82 theca cell tumors. Obstet Gynecol. 1980;55(2):231–8.

    PubMed  Google Scholar 

  97. Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril. 1982;37(1):79–82.

    CAS  PubMed  Google Scholar 

  98. Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol. 1989;161(6 Pt 2):1859–64.

    CAS  PubMed  Google Scholar 

  99. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B, Hoover R, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989;298(6667):147–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  100. Chu J, Schweid AI, Weiss NS. Survival among women with endometrial cancer: a comparison of estrogen users and nonusers. Am J Obstet Gynecol. 1982;143(5):569–73.

    CAS  PubMed  Google Scholar 

  101. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med. 1985;313(16):969–72.

    CAS  PubMed  Google Scholar 

  102. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control. 1999;10(4):277–84.

    CAS  PubMed  Google Scholar 

  103. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA. 2003;290(13):1739–48.

    CAS  PubMed  Google Scholar 

  104. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365(9470):1543–51.

    PubMed  Google Scholar 

  105. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293(23):1164–7.

    CAS  PubMed  Google Scholar 

  106. Stanford JL, Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer. 1993;54(2):243–8.

    CAS  PubMed  Google Scholar 

  107. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 1991;338(8762):274–7.

    CAS  PubMed  Google Scholar 

  108. Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. Obstet Gynecol. 2009;114(6):1197–204.

    CAS  PubMed  Google Scholar 

  109. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators – mechanisms of action and application to clinical practice. N Engl J Med. 2003;348(7):618–29.

    CAS  PubMed  Google Scholar 

  110. Cohen I. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol. 2004;94(2):256–66.

    CAS  PubMed  Google Scholar 

  111. Iqbal J, Ginsburg OM, Wijeratne TD, Howell A, Evans G, Sestak I, et al. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat Rev. 2012;38(4):318–28.

    CAS  PubMed  Google Scholar 

  112. Fornander T, Hellstrom AC, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst. 1993;85(22):1850–5.

    CAS  PubMed  Google Scholar 

  113. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.

    CAS  PubMed  Google Scholar 

  114. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281(23):2189–97.

    CAS  PubMed  Google Scholar 

  115. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.

    Google Scholar 

  116. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11(3):485–90.

    CAS  PubMed  Google Scholar 

  117. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres’ ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet. 2000;356(9233):881–7.

    CAS  PubMed  Google Scholar 

  118. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994;55(2):164–8.

    CAS  PubMed  Google Scholar 

  119. Chin J, Konje JC, Hickey M. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Syst Rev. 2009;(4):Cd007245.

    Google Scholar 

  120. ACOG Committee Opinion No. 601. Tamoxifen and uterine cancer. Obstet Gynecol. 2014;123(6):1394–7.

    Google Scholar 

  121. DeMichele A, Troxel AB, Berlin JA, Weber AL, Bunin GR, Turzo E, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol. 2008;26(25):4151–9.

    PubMed  PubMed Central  Google Scholar 

  122. ACOG Committee Opinion No. 738. Aromatase inhibitors in gynecologic practice. Obstet Gynecol. 2018;131(6):e194–9.

    Google Scholar 

  123. Chlebowski RT, Schottinger JE, Shi J, Chung J, Haque R. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015;121(13):2147–55.

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst. 2011;103(17):1299–309.

    CAS  PubMed  Google Scholar 

  125. Ollikainen M, Abdel-Rahman WM, Moisio AL, Lindroos A, Kariola R, Jarvela I, et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol. 2005;23(21):4609–16.

    CAS  PubMed  Google Scholar 

  126. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol. 2015;125(1):89–98.

    PubMed  Google Scholar 

  127. Sandles LG, Shulman LP, Elias S, Photopulos GJ, Smiley LM, Posten WM, et al. Endometrial adenocarcinoma: genetic analysis suggesting heritable site-specific uterine cancer. Gynecol Oncol. 1992;47(2):167–71.

    CAS  PubMed  Google Scholar 

  128. Berends MJ, Wu Y, Sijmons RH, van der Sluis T, Ek WB, Ligtenberg MJ, et al. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol. 2003;21(23):4364–70.

    CAS  PubMed  Google Scholar 

  129. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009;16(1):14–22.

    PubMed  PubMed Central  Google Scholar 

  130. Lu KH, Dinh M, Kohlmann W, Watson P, Green J, Syngal S, et al. Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005;105(3):569–74.

    PubMed  Google Scholar 

  131. Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 2001;19(20):4074–80.

    CAS  PubMed  Google Scholar 

  132. Vasen HF, Watson P, Mecklin JP, Jass JR, Green JS, Nomizu T, et al. The epidemiology of endometrial cancer in hereditary nonpolyposis colorectal cancer. Anticancer Res. 1994;14(4b):1675–8.

    CAS  PubMed  Google Scholar 

  133. Kwon JS, Scott JL, Gilks CB, Daniels MS, Sun CC, Lu KH. Testing women with endometrial cancer to detect Lynch syndrome. J Clin Oncol. 2011;29(16):2247–52.

    PubMed  PubMed Central  Google Scholar 

  134. Riegert-Johnson DL, Gleeson FC, Roberts M, Tholen K, Youngborg L, Bullock M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract. 2010;8(1):6.

    PubMed  PubMed Central  Google Scholar 

  135. Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. J Med Genet. 2011;48(8):505–12.

    CAS  PubMed  Google Scholar 

  136. Heald B, Mester J, Rybicki L, Orloff MS, Burke CA, Eng C. Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. Gastroenterology. 2010;139(6):1927–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  137. Hornreich G, Beller U, Lavie O, Renbaum P, Cohen Y, Levy-Lahad E. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol. 1999;75(2):300–4.

    CAS  PubMed  Google Scholar 

  138. Barak F, Milgrom R, Laitman Y, Gemer O, Rabinovich A, Piura B, et al. The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. Gynecol Oncol. 2010;119(3):511–5.

    CAS  PubMed  Google Scholar 

  139. Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94(18):1358–65.

    CAS  PubMed  Google Scholar 

  140. Beiner ME, Finch A, Rosen B, Lubinski J, Moller P, Ghadirian P, et al. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007;104(1):7–10.

    CAS  PubMed  Google Scholar 

  141. Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2(11):1434–40.

    PubMed  PubMed Central  Google Scholar 

  142. Cetin I, Cozzi V, Antonazzo P. Infertility as a cancer risk factor – a review. Placenta. 2008;29(Suppl B):169–77.

    PubMed  Google Scholar 

  143. Raglan O, Kalliala I, Markozannes G, et al. Risk factors for endometrial cancer: an umbrella review of the literature [published online ahead of print]. Int J Cancer. 2018. https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.31961. Accessed 29 Apr 2019.

  144. Wu QJ, Li YY, Tu C, Zhu J, Qian KQ, Feng TB, et al. Parity and endometrial cancer risk: a meta-analysis of epidemiological studies. Sci Rep. 2015;5:14243.

    CAS  PubMed  PubMed Central  Google Scholar 

  145. Setiawan VW, Pike MC, Karageorgi S, Deming SL, Anderson K, Bernstein L, et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol. 2012;176(4):269–78.

    PubMed  PubMed Central  Google Scholar 

  146. Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992;167(5):1317–25.

    CAS  PubMed  Google Scholar 

  147. Xu WH, Xiang YB, Ruan ZX, Zheng W, Cheng JR, Dai Q, et al. Menstrual and reproductive factors and endometrial cancer risk: results from a population-based case-control study in urban Shanghai. Int J Cancer. 2004;108(4):613–9.

    CAS  PubMed  Google Scholar 

  148. Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol. 2005;161(7):607–15.

    PubMed  Google Scholar 

  149. Lerner-Geva L, Rabinovici J, Lunenfeld B. Ovarian stimulation: is there a long-term risk for ovarian, breast and endometrial cancer? Womens Health (Lond). 2010;6(6):831–9.

    CAS  PubMed  Google Scholar 

  150. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 1999;354(9190):1586–90.

    CAS  PubMed  Google Scholar 

  151. Jordan SJ, Na R, Johnatty SE, Wise LA, Adami HO, Brinton LA, et al. Breastfeeding and endometrial cancer risk: an analysis from the epidemiology of endometrial cancer consortium. Obstet Gynecol. 2017;129(6):1059–67.

    PubMed  PubMed Central  Google Scholar 

  152. Zhan B, Liu X, Li F, Zhang D. Breastfeeding and the incidence of endometrial cancer: a meta-analysis. Oncotarget. 2015;6(35):38398–409.

    PubMed  PubMed Central  Google Scholar 

  153. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ. 2007;335(7621):651.

    PubMed  PubMed Central  Google Scholar 

  154. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017;216(6):580.e1–9.

    Google Scholar 

  155. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1996;275(5):370–5.

    Google Scholar 

  156. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27 276 women with endometrial cancer from 36 epidemiological studies. Collaborative Group on Epidemiological Studies on Endometrial Cancer. Lancet Oncol. 2015;16(9):1061–70.

    Google Scholar 

  157. Maxwell GL, Schildkraut JM, Calingaert B, Risinger JI, Dainty L, Marchbanks PA, et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol Oncol. 2006;103(2):535–40.

    CAS  PubMed  Google Scholar 

  158. Mueck AO, Seeger H, Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr Relat Cancer. 2010;17(4):R263–71.

    CAS  PubMed  Google Scholar 

  159. Tao MH, Xu WH, Zheng W, Zhang ZF, Gao YT, Ruan ZX, et al. Oral contraceptive and IUD use and endometrial cancer: a population-based case-control study in Shanghai, China. Int J Cancer. 2006;119(9):2142–7.

    CAS  PubMed  Google Scholar 

  160. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95(3):385–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  161. Parslov M, Lidegaard O, Klintorp S, Pedersen B, Jonsson L, Eriksen PS, et al. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol. 2000;182(1 Pt 1):23–9.

    CAS  PubMed  Google Scholar 

  162. Beining RM, Dennis LK, Smith EM, Dokras A. Meta-analysis of intrauterine device use and risk of endometrial cancer. Ann Epidemiol. 2008;18(6):492–9.

    PubMed  Google Scholar 

  163. Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in Finland. Obstet Gynecol. 2014;124(2 Pt 1):292–9.

    CAS  PubMed  Google Scholar 

  164. Felix AS, Brinton LA, McMeekin DS, Creasman WT, Mutch D, Cohn DE, et al. Relationships of tubal ligation to endometrial carcinoma stage and mortality in the NRG Oncology/Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst. 2015;107(9).

    Google Scholar 

  165. Winer I, Lehman A, Wactawski-Wende J, Robinson R, Simon M, Cote M. Tubal ligation and risk of endometrial cancer: findings from the Women’s Health Initiative. Int J Gynecol Cancer. 2016;26(3):464–71.

    PubMed  PubMed Central  Google Scholar 

  166. Hale GE, Hughes CL, Cline JM. Endometrial cancer: hormonal factors, the perimenopausal “window of risk,” and isoflavones. J Clin Endocrinol Metab. 2002;87(1):3–15.

    CAS  PubMed  Google Scholar 

  167. Bandera EV, Williams MG, Sima C, Bayuga S, Pulick K, Wilcox H, et al. Phytoestrogen consumption and endometrial cancer risk: a population-based case-control study in New Jersey. Cancer Causes Control. 2009;20(7):1117–27.

    PubMed  PubMed Central  Google Scholar 

  168. Mulholland HG, Murray LJ, Cardwell CR, Cantwell MM. Dietary glycaemic index, glycaemic load and endometrial and ovarian cancer risk: a systematic review and meta-analysis. Br J Cancer. 2008;99(3):434–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  169. Unfer V, Casini ML, Costabile L, Mignosa M, Gerli S, Di Renzo GC. Endometrial effects of long-term treatment with phytoestrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril. 2004;82(1):145–8, quiz 265

    CAS  PubMed  Google Scholar 

  170. Bandera EV, Kushi LH, Moore DF, Gifkins DM, McCullough ML. Consumption of animal foods and endometrial cancer risk: a systematic literature review and meta-analysis. Cancer Causes Control. 2007;18(9):967–88.

    PubMed  PubMed Central  Google Scholar 

  171. The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010). Menopause. 2011;18(7):732–53.

    Google Scholar 

  172. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol. 1997;146(4):294–306.

    CAS  PubMed  Google Scholar 

  173. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003;95(15):1158–64.

    CAS  PubMed  Google Scholar 

  174. Ollberding NJ, Lim U, Wilkens LR, Setiawan VW, Shvetsov YB, Henderson BE, et al. Legume, soy, tofu, and isoflavone intake and endometrial cancer risk in postmenopausal women in the multiethnic cohort study. J Natl Cancer Inst. 2012;104(1):67–76.

    CAS  PubMed  Google Scholar 

  175. Grant WB, Garland CF. The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Res. 2006;26(4a):2687–99.

    CAS  PubMed  Google Scholar 

  176. McCullough ML, Bandera EV, Moore DF, Kushi LH. Vitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature. Prev Med. 2008;46(4):298–302.

    CAS  PubMed  Google Scholar 

  177. Moore SC, Gierach GL, Schatzkin A, Matthews CE. Physical activity, sedentary behaviours, and the prevention of endometrial cancer. Br J Cancer. 2010;103(7):933–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  178. Schmid D, Behrens G, Keimling M, Jochem C, Ricci C, Leitzmann M. A systematic review and meta-analysis of physical activity and endometrial cancer risk. Eur J Epidemiol. 2015;30(5):397–412.

    CAS  PubMed  Google Scholar 

  179. Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer. 2003;104(6):669–76.

    CAS  PubMed  Google Scholar 

  180. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007;50(7):1365–74.

    CAS  PubMed  Google Scholar 

  181. Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer. 2008;98(9):1582–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  182. Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol. 1998;148(3):234–40.

    CAS  PubMed  Google Scholar 

  183. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer. 2006;106(11):2376–81.

    CAS  PubMed  Google Scholar 

  184. Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol. 1998;179(1):6–12.

    CAS  PubMed  Google Scholar 

  185. Friberg E, Mantzoros CS, Wolk A. Diabetes and risk of endometrial cancer: a population-based prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16(2):276–80.

    PubMed  Google Scholar 

  186. Zhang Y, Liu Z, Yu X, Zhang X, Lu S, Chen X, et al. The association between metabolic abnormality and endometrial cancer: a large case-control study in China. Gynecol Oncol. 2010;117(1):41–6.

    CAS  PubMed  Google Scholar 

  187. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension. 1999;34(2):320–5.

    CAS  PubMed  Google Scholar 

  188. Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang N, et al. Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med. 2008;121(6):501–8.e3.

    CAS  PubMed  Google Scholar 

  189. Loerbroks A, Schouten LJ, Goldbohm RA, van den Brandt PA. Alcohol consumption, cigarette smoking, and endometrial cancer risk: results from the Netherlands Cohort Study. Cancer Causes Control. 2007;18(5):551–60.

    PubMed  PubMed Central  Google Scholar 

  190. Sun Q, Xu L, Zhou B, Wang Y, Jing Y, Wang B. Alcohol consumption and the risk of endometrial cancer: a meta-analysis. Asia Pac J Clin Nutr. 2011;20(1):125–33.

    PubMed  Google Scholar 

  191. Bravi F, Scotti L, Bosetti C, Gallus S, Negri E, La Vecchia C, et al. Coffee drinking and endometrial cancer risk: a metaanalysis of observational studies. Am J Obstet Gynecol. 2009;200(2):130–5.

    PubMed  Google Scholar 

  192. Yu X, Bao Z, Zou J, Dong J. Coffee consumption and risk of cancers: a meta-analysis of cohort studies. BMC Cancer. 2011;11:96.

    PubMed  PubMed Central  Google Scholar 

  193. Tang NP, Li H, Qiu YL, Zhou GM, Ma J. Tea consumption and risk of endometrial cancer: a metaanalysis. Am J Obstet Gynecol. 2009;201(6):605.e1–8.

    PubMed  Google Scholar 

  194. Yang TO, Crowe F, Cairns BJ, Reeves GK, Beral V. Tea and coffee and risk of endometrial cancer: cohort study and meta-analysis. Am J Clin Nutr. 2015;101(3):570–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  195. Je Y, Hankinson SE, Tworoger SS, De Vivo I, Giovannucci E. A prospective cohort study of coffee consumption and risk of endometrial cancer over a 26-year follow-up. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2487–95.

    PubMed  PubMed Central  Google Scholar 

  196. Matsuo K, Cahoon SS, Yoshihara K, Shida M, Kakuda M, Adachi S, et al. Association of low-dose aspirin and survival of women with endometrial cancer. Obstet Gynecol. 2016;128(1):127–37.

    CAS  PubMed  Google Scholar 

  197. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM. Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer. 2013;132(5):1146–55.

    CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare that they have no conflicts of interest associated with this manuscript.

Financial Disclosures

None to disclose.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Medical College of Georgia, Augusta University, Augusta, GA, USA

    Thomas A. Paterniti

  2. Florida State University College of Medicine, Tallahassee, FL, USA

    Thomas A. Paterniti, Evan A. Schrader, Emily Deibert, Elizabeth A. Wilkinson & Sarfraz Ahmad

  3. Department of Obstetrics and Gynecology, Wake Forest School of Medicine, Winston-Salem, NC, USA

    Emily Deibert

  4. Department of Obstetrics and Gynecology, University of Florida College of Medicine, Gainesville, FL, USA

    Elizabeth A. Wilkinson

  5. AdventHealth Gynecologic Oncology, AdventHealth Cancer Institute, Orlando, FL, USA

    Sarfraz Ahmad

  6. University of Central Florida College of Medicine, Orlando, FL, USA

    Sarfraz Ahmad

Authors
  1. Thomas A. Paterniti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Evan A. Schrader
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emily Deibert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elizabeth A. Wilkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sarfraz Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics & Gynecology, Babu Jagjivan Ram Memorial Hospital, New Delhi, India

    Sumita Mehta

  2. Obstetrics and Gynecology, UCMS & GTB Hospital, Delhi, India

    Bindiya Gupta

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Paterniti, T.A., Schrader, E.A., Deibert, E., Wilkinson, E.A., Ahmad, S. (2020). Changing Trends in the Epidemiology of Endometrial Cancer. In: Mehta, S., Gupta, B. (eds) Recent Advances in Endometrial Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-15-5317-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-5317-2_1

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-5316-5

  • Online ISBN: 978-981-15-5317-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation